241 related articles for article (PubMed ID: 35982032)
41. Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study.
Korshoej AR; Hansen FL; Thielscher A; von Oettingen GB; Sørensen JCH
PLoS One; 2017; 12(6):e0179214. PubMed ID: 28604803
[TBL] [Abstract][Full Text] [Related]
42. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
43. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.
Kim JY; Jo Y; Oh HK; Kim EH
Am J Cancer Res; 2020; 10(10):3475-3486. PubMed ID: 33163284
[TBL] [Abstract][Full Text] [Related]
44. Tumor treating fields: a novel treatment modality and its use in brain tumors.
Hottinger AF; Pacheco P; Stupp R
Neuro Oncol; 2016 Oct; 18(10):1338-49. PubMed ID: 27664860
[TBL] [Abstract][Full Text] [Related]
45. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
46. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X; Liu K; Xing L; Rubinsky B
Radiol Oncol; 2023 Sep; 57(3):279-291. PubMed ID: 37665740
[TBL] [Abstract][Full Text] [Related]
47. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions.
Simchony H; Diamant D; Ram Z; Volovitz I
Isr Med Assoc J; 2019 Jul; 21(7):503. PubMed ID: 31507132
[TBL] [Abstract][Full Text] [Related]
49. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
[TBL] [Abstract][Full Text] [Related]
50. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract][Full Text] [Related]
51. A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
Kumthekar P; Lyleroehr M; Lacson L; Lukas RV; Dixit K; Stupp R; Kruser T; Raizer J; Hou A; Sachdev S; Schwartz M; Pa JB; Lezon R; Schmidt K; Amidei C; Kaiser K
BMC Cancer; 2024 Apr; 24(1):527. PubMed ID: 38664630
[TBL] [Abstract][Full Text] [Related]
52. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study.
Wenger C; Salvador R; Basser PJ; Miranda PC
Phys Med Biol; 2015 Sep; 60(18):7339-57. PubMed ID: 26350296
[TBL] [Abstract][Full Text] [Related]
53. Computed modeling of alternating electric fields therapy for recurrent glioblastoma.
Lok E; Hua V; Wong ET
Cancer Med; 2015 Nov; 4(11):1697-9. PubMed ID: 26311253
[TBL] [Abstract][Full Text] [Related]
54. Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies.
Berger TR; Wong ET
Chin Clin Oncol; 2021 Aug; 10(4):36. PubMed ID: 32156119
[TBL] [Abstract][Full Text] [Related]
55. The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M; Ballo MT; Bomzon Z; Urman N; Levi S; Lavy-Shahaf G; Jeyapalan S; Sio TT; DeRose PM; Misch M; Taillibert S; Ram Z; Hottinger AF; Easaw J; Kim CY; Mohan S; Stupp R
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1269-1278. PubMed ID: 34963556
[TBL] [Abstract][Full Text] [Related]
56. Improving Tumor Treating Fields Treatment Efficacy in Patients With Glioblastoma Using Personalized Array Layouts.
Wenger C; Salvador R; Basser PJ; Miranda PC
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1137-43. PubMed ID: 26883559
[TBL] [Abstract][Full Text] [Related]
57. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
58. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
59. Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP; Shin D; Melnick K; Tran DD
Curr Treat Options Oncol; 2020 Jul; 21(9):76. PubMed ID: 32734509
[TBL] [Abstract][Full Text] [Related]
60. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
